Telitacicept Gets Fourth Approval in China, But Vor's Global Story Remains a Wait

What happened

Vor Bio's collaborator RemeGen secured conditional NMPA approval for telitacicept in IgAN, marking the fourth China approval across autoimmune indications. The approval bolsters the drug's clinical evidence base but has no immediate impact on Vor's ex-China rights or its global Phase 3 gMG trial timeline. Vor's stock has rallied 50%+ over the past year on telitacicept momentum, but the master report flags a still-distant 1H27 gMG readout, a 2028 patent cliff, and a warrant-heavy capital structure. The IgAN approval is incrementally positive, yet it does not alter the fundamental risk-reward: Vor remains a single-asset biotech requiring flawless execution and further capital discipline to avoid dilution. Investors should maintain a wait stance until price resets closer to cash-adjusted downside or clear enrollment metrics de-risk the pivotal gMG trial.

Implication

While the fourth approval in China adds to telitacicept's credibility, Vor’s ex-China value hinges on global Phase 3 gMG data due in 1H27—over a year away. The company must also navigate a narrow patent window and large milestone/royalty obligations to RemeGen. Near-term catalysts are incremental, and any equity raise before that readout would likely be dilutive. We see better risk-reward waiting for price weakness or clearer execution proof.

Thesis delta

The IgAN approval reinforces telitacicept's multi-indication potential, reducing regulatory risk in China but leaving the ex-China commercial thesis unchanged. The core investment case still depends on successful global gMG pivotal data and capital discipline, which will not be resolved for 12-18 months. Therefore, the wait stance remains appropriate, as the stock's current valuation still prices in significant optimism without near-term catalysts.